CLINUVEL's company releases, including archives.

Wednesday, 12 December 2018 18:56

CLINUVEL Newsletter - December 2018

Wednesday, 21 November 2018 11:37

Results of Meeting

Wednesday, 21 November 2018 10:21

Managing Director AGM Presentation

Wednesday, 21 November 2018 10:14

Chair's Address to the Annual General Meeting

Monday, 05 November 2018 18:04

CLINUVEL Newsletter - November 2018

Wednesday, 31 October 2018 19:20

Appendix 4C

Appendix 4C Melbourne, Australia and Leatherhead, UK, 31 October 2018 CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 July to 30 September 2018. All figures are rounded and reported in Australian dollars. Cash receipts from customers for the quarter were $10,705,000, an 89% increase compared to the same quarter last year ($5,638,000 for the July to September 2017 quarter) and a 3% increase compared to the previous quarter ($10,388,000 for the…
CLINUVEL expands Singapore laboratory facilities Analytical capability established for follow-on innovative product lines at VALLAURIX, a fully owned subsidiary Summary • VALLAURIX laboratory expansion, addition of critical analytical methodologies • Supply chain integration as part of CLINUVEL’s commercial objectives • VALLAURIX focus on development of CUV9900, VLRX001 and OTC products • Laboratory research on topical and paediatric formulation Melbourne, Australia and Singapore, 29 October 2018 CLINUVEL PHARMACEUTICALS LTD today announced that its fully owned Singaporean subsidiary VALLAURIX PTE LTD is expanding its laboratory facilities to incorporate a variety of critical analytical functions. As part of the increase in research activities…
Friday, 19 October 2018 00:00

Notice of Annual General Meeting/Proxy Form

APPEAL UPHELD AGAINST NICE RECOMMENDATION IN ENGLAND Appeal Panel remits to NICE evaluation committee to readdress the assessment underlying the reimbursement of SCENESSE® for the treatment of English EPP patients Melbourne, Australia and Leatherhead, UK, 10 October 2018 CLINUVEL PHARMACEUTICALS LTD today announced that the Appeal Panel of the National Institute of Health and Care Excellence (NICE) – the body responsible for providing evidence-based guidance on health and social care to the National Health Service (NHS) in England – has published a decision following an oral Appeal Hearing as part of the ongoing Highly Specialised Technology (HST) evaluation of CLINUVEL’s…
Page 1 of 13